FTSE 100 Index Ends the Quarter 2.84% Higher at 7952.62 — Data Talk
The FTSE 100 Index is up 219.38 points or 2.84% this quarter to 7952.62
--Largest one quarter point and percentage gain since the 4th Qtr 2022
--Up for three consecutive quarters
--Up 421.09 points or 5.59% over the last three quarters
--Largest three quarter point and percentage gain since the 2nd Qtr 2023
--Up five of the past six quarters
--This month it is up 322.60 points or 4.23%
--Largest one month point gain since Nov. 2022
--Largest one month percentage gain since Jan. 2023
--Snaps a two month losing streak
--This week it is up 21.70 points or 0.27%
--Up for three consecutive weeks
--Up 292.88 points or 3.82% over the last three weeks
--Largest three week point and percentage gain since the week ending Sept. 15, 2023
--Today it is up 20.64 points or 0.26%
--Largest one day point and percentage gain since Friday, March 22, 2024
--Up for three consecutive trading days
--Up 35.05 points or 0.44% over the last three trading days
--Largest three day point and percentage gain since Tuesday, March 26, 2024
--Up five of the past six trading days
--Off 0.77% from its record close of 8014.31 hit Monday, Feb. 20, 2023
--Up 25.47% since the pre-Brexit vote level of 6338.10 hit Thursday, June 23, 2016
--A new 52-week high
--Highest closing value since Tuesday, Feb. 21, 2023
--Up 9.59% from its 52-week low of 7256.94 hit Friday, July 7, 2023
--Rose 4.36% from 52 weeks ago
--Up 6.80% from its 2024 closing low of 7446.29 hit Wednesday, Jan. 17, 2024
--Year-to-date it is up 219.38 points or 2.84%
Source: Dow Jones Market Data, FactSet
(END) Dow Jones Newswires
March 28, 2024 13:53 ET (17:53 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
5 Stocks to Buy That We Still Like After They’ve Run Up
-
Markets Brief: Stocks Are Starting to Look Cheap Again
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
-
Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track
-
American Airlines Earnings: We See Costs Overshadowing Market Share This Year
-
Snap Earnings: Advertising Growth and Snapchat+ Drive Monetization
-
STMicro Earnings: We Still See an Attractive Margin of Safety Despite a Poor First-Half Forecast
-
Alphabet Shares Surge on Strong Earnings, Dividend Surprise
-
Microsoft Earnings: Firm Beats Forecasts on Strong AI and Cloud Demand
-
PG&E Earnings: Near-Term Regulatory Certainty Supports Industry-Leading Earnings Growth